title: [Recombinant adeno-associated virus vector related impurities].
abstract: Recombinant adeno-associated virus (rAAV)-based vectors that can stably express therapeutic genes in vivo without detectable side-effect have shown great promise for human gene therapy. A major challenge for translation of promising research to clinical development is how to establish clinically compatible purification methods in separating rAAV from potentially pathogenic impurities, especially rAAV vector-related impurities, a class of impurities corresponding to AAV particles that closely resemble bona fide vectors and are difficult to remove. In this review we summarize the assembly process of rAAV vector-related impurities and their characteristics differed with rAAV vectors, and evaluate several current technologies to prevent their formation or separate them from rAAV stocks.
authors.affiliation: Engineering Research Center of Molecular Medicine, Ministry of Education, Institute of Molecular Medicine, Huaqiao University, Quanzhou 362021, China. diaoyong@hqu.edu.cn
authors.forename: Yong
authors.initials: Y
authors.lastname: Diao
authors.forename: Qizhao
authors.initials: Q
authors.lastname: Wang
authors.forename: Weidong
authors.initials: W
authors.lastname: Xiao
authors.forename: Rui'an
authors.initials: R
authors.lastname: Xu
mesh_terms: D036022:Capsid Proteins / Q000302:isolation & purification*; D000229:Dependovirus / Q000235:genetics* / Q000302:isolation & purification / Q000502:physiology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics* / Q000302:isolation & purification; D011995:Recombination, Genetic; D014771:Virion / Q000302:isolation & purification; D019065:Virus Assembly / Q000235:genetics; D014779:Virus Replication / Q000235:genetics
chemical_list: D036022:Capsid Proteins